Pancreatic neoplasms

Current Opinion in Gastroenterology

Volumn 20, Issue 5, 2004, Pages 452-458

  Hines, Oscar J ^a   Reber, Howard A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autoimmune pancreatitis; Cystic tumor adjuvant therapy; Intraductal papillary mucinous tumor; Pancreatic adenocarcinoma; Pancreatic neoplasm

Indexed keywords

ALPHA INTERFERON; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 6; CISPLATIN; FASCIN; FLUOROURACIL; GEMCITABINE; GENISTEIN; IMMUNOGLOBULIN; ISOFLAVONOID; KALLIKREIN; KALLIKREIN 10; MESOTHELIN; MUCIN 4; MUCIN 5AC; PROTEIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; STEROID; STRATIFIN; TMPRSS3 PROTEIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANGIOGRAPHY; ARTERY THROMBOSIS; ASPIRATION BIOPSY; AUTOIMMUNE DISEASE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CARCINOMATOSIS; CHEMOTHERAPY INDUCED EMESIS; COMPUTER ASSISTED TOMOGRAPHY; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; HUMAN; INFECTION; LIVER METASTASIS; MASS SPECTROMETRY; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS CYST; PROSTATE CANCER; PROTEOMICS; RADIATION DOSE; RADIATION INDUCED EMESIS; RADIATION INJURY; REVIEW; SIDE EFFECT; SUPERIOR MESENTERIC ARTERY; WEIGHT REDUCTION;

EID: 4344610655     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200409000-00006     Document Type: Review

References (25)

1. Jemal A, Tiwari RC, Murray T, et al.: Cancer statistics, 2004. CA Cancer J Clin 2004, 54:8-29.
2. Hingorani SR, Petricoin EF, Maitra A, et al.: Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003, 4:437-450. This paper describes a transgenic mouse model directed at pancreatic KRAS that spontaneously forms PanINs and eventually pancreatic cancer. This type of model could be used for preventive and therapeutic investigation.
3. Ammori JB, Colletti LM, Zalupski MM, et al.: Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. J Gastrointest Surg 2003, 7:766-772.
4. Hotz HG, Reber HA, Hotz B, et al.: An orthotopic nude mouse model for evaluating pathophysiology and therapy of pancreatic cancer. Pancreas 2003, 26:e89-e98.
5. Buchler P, Reber HA, Buchler MW, et al.: Antiangiogenic activity of genistein in pancreatic carcinoma cells is mediated by the inhibition of hypoxia-inducible factor-1 and the down-regulation of VEGF gene expression. Cancer 2004, 100:201-210.
6. Duxbury MS, Ito H, Ashley SW, et al.: CEACAM6 as a novel target for indirect type 1 immunotoxin-based therapy in pancreatic adenocarcinoma. Biochem Biophys Res Commun 2004, 317:837-843. This study demonstrated that the inhibition of CEACAM6 resulted in smaller tumors in vivo and made the cancer cells more susceptible to normal cellular death mechanisms.
7. Iacobuzio-Donahue CA, Ashfaq R, Maitra A, et al.: Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 2003, 63:8614-8622.
8. Soriano A, Castells A, Ayuso C, et al.: Preoperative staging and tumor resectability assessment of pancreatic cancer: prospective study comparing endoscopic ultrasonography, helical computed tomography, magnetic resonance imaging, and angiography. Am J Gastroenterol 2004, 99:492-501.
9. Micames C, Jowell PS, White R, et al.: Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA. Gastrointest Endosc 2003, 58:690-695.
10. Ammori JB, Colletti LM, Zalupski MM, et al.: Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. J Gastrointest Surg 2003, 7:766-772.
11. Magnin V, Moutardier V, Giovannini MH, et al.: Neoadjuvant preoperative chemoradiation in patients with pancreatic cancer. Int J Radiat Oncol Biol Phys 2003, 55:1300-1304.
12. Kuhlmann KF, de Castro SM, Wesseling JG, et al.: Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. Eur J Cancer 2004, 40:549-558.
13. Stojadinovic A, Brooks A, Hoos A, et al.: An evidence-based approach to the surgical management of resectable pancreatic adenocarcinoma. J Am Coll Surg 2003, 196:954-964.
14. Ali S, Ammori BJ: Concomitant laparoscopic gastric and biliary bypass and bilateral thoracoscopic splanchnotomy: the full package of minimally invasive palliation for pancreatic cancer. Surg Endosc 2003, 17:2028-2031.
15. Mittal A, Windsor J, Woodfield J, et al.: Matched study of three methods for palliation of malignant pyloroduodenal obstruction. Br J Surg 2004, 91:205-209.
16. Neoptolemos JP, Stocken DD, Friess H, et al.: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004, 350:1200-1210. This randomized prospective trial represents one of the largest trials ever investigating adjuvant 5-fluorouracil and radiotherapy for pancreatic cancer. The authors conclude that chemotherapy is useful but chemoradiation may be harmful in patients treated after resection.
17. Hu YC, Komorowski RA, Graewin S, et al.: Thymidylate synthase expression predicts the response to 5-fluorouracil-based adjuvant therapy in pancreatic cancer. Clin Cancer Res 2003, 9:4165-4171.
18. Picozzi VJ, Kozarek RA, Traverso LW: Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 2003, 185:476-480. These investigators describe an interferon-based adjuvant therapy with actuarial survival at 1-year, 2-year, and 5-year periods of 95%, 64%, and 55%, respectively. This trial is now the focus of a larger study by the American College of Surgeons Oncology Group.
19. Ziske C, Schlie C, Gorschluter M, et al.: Prognostic value of CA19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer 2003, 89:1413-1417.
20. D'Angelica M, Brennan MF, Suriawinata AA: Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome. Ann Surg 2004, 239:400-408.
21. Wiesenauer CA, Schmidt CM, Cummings OW, et al.: Preoperative predictors of malignancy in pancreatic intraductal papillary mucinous neoplasms. Arch Surg 2003, 138:610-617.
22. Norton JA, Warren RS, Kelly MG, et al.: Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 2003, 134:1057-1063.
23. Kloppel G, Luttges J, Lohr M, et al.: Autoimmune pancreatitis: pathological, clinical, and immunological features. Pancreas 2003, 27:14-19.
24. Fernandez-del Castillo C, Targarona J, Thayer SP, et al.: Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patients. Arch Surg 2003, 138:427-433. This group, known for their expertise in cystic lesions of the pancreas, reports that in patients with asymptomatic lesions less than 2 cm, the rate of premalignant cysts was as high as 46%. This calls into question the role of watchful waiting in the management of these lesions.
25. Allen PJ, Jaques DP, D'Angelica M, et al.: Cystic lesions of the pancreas: selection criteria for operative and nonoperative management in 209 patients. J Gastrointest Surg 2003, 7:970-977.